Category: MS Research Study and Reports

Unraveling the substrates of cognitive impairment in multiple sclerosis: A multiparametric structural and functional magnetic resonance imaging study

 Lorenzo Conti 1, Paolo Preziosa 1 2, Alessandro Meani 1, Elisabetta Pagani 1, Paola Valsasina 1, Olga Marchesi 1, Carmen Vizzino 1, Maria A Rocca 1 2 3, Massimo Filippi 1 2 3 4 5 PMID: 34255918   DOI: 10.1111/ene.15023 PubMed Abstract Background: Cognitive impairment frequently affects…

Stuart Schlossman

Newer MS diagnostic criteria show ‘prognostic improvement’

 September 27, 2021 Researchers observed a continuous decrease in the time to MS diagnosis and treatment initiation across diagnostic criteria…

Stuart Schlossman

Research News: Hospital Visits for People With MS Rise as Temperatures Increase, Study Finds

 Medically reviewed by Evelyn O. Berman, M.D. Article written by Torrey Kim October 05, 2021 In a recent retrospective study, researchers analyzed…

Stuart Schlossman

Hydroxychloroquine for Primary Progressive Multiple Sclerosis

  Abstract Objective: Primary progressive multiple sclerosis (PPMS) does not respond well to immunomodulatory or immunosuppressive treatment. Chronic activation of microglia…

Stuart Schlossman

Alarming COVID study indicates long-term loss of gray matter and other brain tissue

 By Michael Greenwood, M.Sc.          Jun 18 2021 There has been extensive evidence of brain-related pathologies associated with COVID-19…

Stuart Schlossman

Multiple Sclerosis Linked to Infection in Adolescence

September 7, 2021 Summary:  A new study links viral infections including mononucleosis and pneumonia experienced during adolescence with an increased risk…

Stuart Schlossman

BTK Inhibitor Reduces New Lesions in Relapsing Multiple Sclerosis

 Tolebrutinib may hold promise for progressive MS, too by Judy George, Senior Staff Writer, MedPage Today September 3, 2021    Tolebrutinib, a…

Stuart Schlossman

Overcoming Obstacles to Promote Repair in Multiple Sclerosis

Tue, August 24, 2021, 1:21 PM·8 min read Study points to a new promising therapy against toxic blood leaks in…

Stuart Schlossman

Tolebrutinib Shows Dose-Dependent MS Lesion Reduction in Phase 2b Trial

 August 26, 2021    Marco Meglio The results support continued development of tolebrutinib 60 mg in phase 3 trials for MS,…

Stuart Schlossman

Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis

 Marcus W Koch 1 2, Jop P Mostert 3, Jerry S Wolinsky 4, Fred D Lublin 5, Bernard Uitdehaag 6, Gary R Cutter 7 Affiliations expand PMID: 34433679   DOI: 10.1212/WNL.0000000000012690 Abstract Background: Clinical trials in…

Stuart Schlossman

Categories

Latest Blog Posts